Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy

Study of Saroglitazar Magnesium for PBC Patients with Incomplete Response or Intolerant to UDCA Therapy

Participants needed: 89
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Zydus Therapeutics Inc.Updated: May 12, 2026
Eligibility criteria

Adults between 18 and 80 years of age (both inclusive at screening) [+5]

Consumption of 14 or more standard alcohol drinks per week if male and 7 or more... [+26]

Read more
Status: Not yet recruiting

Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes

Long-Term Study to Evaluate the Safety and Efficacy in Participants with Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes (EPICS-V)

Participants needed: 386
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Zydus Therapeutics Inc.Updated: Feb 18, 2026
Eligibility criteria

Is capable of understanding the written informed consent, provides signed and wi... [+3]

Has consumption of 2 standard alcohol drinks per day (or 14 alcohol drinks per w... [+8]

Read more
Status: Recruiting

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease

Participants needed: 30
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Zydus Therapeutics Inc.Updated: Feb 17, 2026Locations: 1
Eligibility criteria

Ability to comprehend and willingness to sign a written ICF for the study. [+13]

Any significant, unstable medical condition or other instability that would prev... [+23]

Read more
Status: Recruiting

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

Evaluating Pharmacokinetic and safety of Saroglitazar Magnesium 1 mg when dosed on alternate days in subjects having moderate hepatic impairment with cirrhosis due to cholestatic liver disease

Participants needed: 6
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Zydus Therapeutics Inc.Updated: Oct 24, 2025Locations: 1
Eligibility criteria

Male and/or female aged 18 to 80 years (both inclusive) at the time of signing t... [+4]

Any significant or unstable medical condition or other instability that would pr... [+14]

Read more